Healthcare Industry News: Orthofix
News Release - September 28, 2010
Predictive Biosciences Appoints New Members to Leadership TeamSupports Launch Efforts for Novel Bladder Cancer Test
LEXINGTON, Mass.--(Healthcare Sales & Marketing Network)--Predictive Biosciences, a fully-integrated developer of novel molecular diagnostic cancer assays and a provider of anatomic pathology products and services, today announced the expansion of the company’s leadership team with the appointment of Thomas M. Ross as chief commercial officer, and Randal Vader as vice president of clinical and regulatory affairs.
As chief commercial officer, Mr. Ross has more than 20 years of operational management and direct sales experience in the medical diagnostics industry. Mr. Ross recently served as vice president of North American MDX Sales at QIAGEN, where he managed their major product lines and helped establish QIAGEN as a leader in infectious disease testing. Previously at Digene (acquired by QIAGEN), Mr. Ross was responsible for driving rapid expansion of physician and laboratory sales.
Mr. Vader brings more than 20 years of global regulatory affairs, clinical affairs and quality systems experience in the medical device and diagnostic industry. Most recently, he served as senior vice president, quality, regulatory and clinical affairs at Orthofix, where he was responsible for full regulatory compliance for the company. Previously at EraGen Biosciences, Mr. Vader collaborated closely with the U.S. Food and Drug Administration to successfully obtain FDA clearance for the first herpes simplex virus (HSV) molecular diagnostic test in the United States.
“We are pleased to have such highly experienced medical diagnostics executives such as Thomas and Randy on the Predictive Biosciences team,” stated Peter Klemm, Ph.D., president and chief executive officer. “They will play an instrumental role in the launch of our CertNDxTM Bladder Cancer Test as well as the strategic vision of the company.”
Predictive’s urinary biomarker based assay for bladder cancer is the first in its unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence, allowing certain groups of patients to be excluded from undergoing invasive procedures such as cystoscopy.
About Predictive Biosciences
Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays and an urology-focused provider of anatomic pathology laboratory products and services. Leveraging a portfolio of patented biomarkers and clinical approaches, the company is building a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. Predictive Biosciences’ commercial division, OncoDiagnostic Laboratory (ODL), is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists and other subspecialty physicians. For additional information, please visit www.predictivebiosci.com.
Source: Predictive Biosciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.